News Archives - Page 224 of 721

MondayNov 14, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of…

MondayNov 14, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin

In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study that saw 44% of the patients post a clinical response, with one Durable Complete Response With GBM having a survival rate of only 6.8% and an average length of survival of only eight months, Berubicin is showing tremendous potential, and CNS is leading the charge to find a potential treatment option for the disease CNS’ management is optimistic about its lead drug candidate and continues to explore the potential…

MondayNov 14, 2022 9:00 am

Company Profile: Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM)

Eloro Resources Ltd. Owns a 98% interest in Minera Tupiza with an option to acquire 99% interest in a neighboring highly sought after, royalty-free property in southern Bolivia Eloro has an option to acquire a 99% interest in the 9 square km, highly prospective Iska Iska Property, which hosts a major silver-tin polymetallic porphyry-epithermal complex located 4,000m above sea level Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), a publicly traded exploration and mine development company, established in 1985 with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Polymetallic Project in Bolivia Bolivia’s modern mining…

FridayNov 11, 2022 10:30 am

Freight Technologies Inc.’s (NASDAQ: FRGT) Capacity Planning Product Poised for Tremendous Growth Following Two-Year Commitment from Shipper Partner

Freight Technologies recently announced receipt of a two-year commitment from Kimberly Clark De Mexico, SAB de CV (“KCM”), that will significantly expand its Fr8PrivateFleet product Fr8Tech introduced Fr8PrivateFleet at the end of 2021 through its wholly owned subsidiary Freight App, Inc.capacity The product solves shippers’ need to secure freight over time rather than on a trip-by-trip basis and provides carriers, who can deliver the shipper’s loads based on this criterion, with a steady stream of employment opportunities and revenue The two-year commitment is set to more than triple Fr8Tech’s capacity in the Fr8PrivateFleet product over three months Freight Technologies (NASDAQ:…

FridayNov 11, 2022 9:45 am

GeoSolar Technologies Inc. Appears Well-Positioned Within America’s Energy Transition, Empowering Homeowners to Join the Electric Revolution

Solar is blooming; from 2020 to 2021, residential solar power grew by 34% In 2022, Americans are increasingly going solar for environmental, health and financial reasons: 8% of US surveyed homeowners have installed solar panels – up from 6% in 2019 and 4% in 2016 GeoSolar is poised to capitalize on this growth potential with its SmartGreen(TM) Home system that helps American homeowners tackle both environmental and financial issues at once In a world unsettled by rising fuel costs and heightened energy uncertainty, solar emerges as part of a potential solution. Consequently, the sector is booming, transforming from a niche…

FridayNov 11, 2022 9:00 am

Zacks SCR Uses Lexaria Bioscience Corp. (NASDAQ: LEXX) HYPER-H21-4 Study to Support $15 Share Valuation

Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placebo According to a Zacks SCR report, the findings support their $15 share valuation of the company Zacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral products The hypertension drug market is expected to grow to over $34 billion through 2030, with North America anticipated to hold 35% of the market share According to the World Health Organization (“WHO”), approximately 1.13 billion people worldwide suffer from hypertension (high blood pressure), with only one…

ThursdayNov 10, 2022 11:15 am

Specialized Market Lender REZYFi, Inc. Believes They Have Real Opportunity Amid Challenges Faced by Traditional Lenders

While economies worldwide are struggling to control spiking inflation rates, REZYFi, a mortgage lender servicing non-traditional as well as other loans, sees unique financial opportunities Through the use of proprietary automated machine learning and associated technologies, together with preparations to launch a high-margin cannabis division later this year to serve an industry in need of loan origination options, REZYFi is working to grow its operation RZFI is licensed in more than 30 U.S. states and expects to expand its loan origination services to all remaining states in coming months Economic challenges resulting from governmental efforts to tame inflation could in…

ThursdayNov 10, 2022 10:30 am

As World Pollutant Concerns Grow, Correlate Infrastructure Partners Inc. (CIPI) Helps Drive Optimism for Affordable and Effective ESG Solutions

Climate change and industrialized pollution emissions continue to raise warnings worldwide that the quality of human life is being compromised U.S.-based Correlate Infrastructure Partners is working to establish solutions for its clients by assessing utilities inefficiencies, advising on affordable improvements, and then helping to successfully implement changes through access to highly cost-effective financing opportunities The federal government’s recent passage of greenhouse gas reduction financing opportunities through the Inflation Reduction Act (“IRA”) has established the government as a ready partner in companies’ ESG policies The IRA has become particularly attractive to public, non-profit, and REIT entities because of changes to subsidy…

ThursdayNov 10, 2022 9:45 am

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) Offers Fully Compliant Data Solutions, CPRA Data Law Set to Take Effect on January 1, 2023

The CCPA limits data flows to brands and marketers, and CPRA amendments are set to take effect January 1, 2023 CPRA and CCPA provisions include the right to opt-out of data sharing and sale, as well as the right to data deletion Consumer data is critical to branding and advertising strategies Reklaim provides an ecosystem that equips marketers with fully compliant, consumer-verified data sets while rewarding consumers for sharing information With the aim of protecting consumers, the California Consumer Privacy Act (“CCPA”) and amendments provided by the California Privacy Rights Act (“CPRA”) are gradually transforming the advertising landscape by limiting…

ThursdayNov 10, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM

CNS Pharmaceuticals is focused on advancing its clinical development for the Berubicin drug candidate in order to bring meaningful treatment to GBM patients GBM, which has a low survival rate, has limited treatment options when it progresses after first-line therapy The company is looking to find a solution with Berubicin and is currently evaluating this drug candidate in a potentially pivotal global study CNS’s ongoing R&D efforts are boosted by its strong cash position; in its Q2 2022 report, the company announced it had cash of about $9.0 million and working capital of $10.5 million CNS Pharmaceuticals (NASDAQ: CNSP), an…

Site Search

Company Search

Category: News